AMDL Inc. is a Tustin-based pharmaceutical company committed to research, development, manufacturing and marketing of diagnostic, pharmaceutical, nutritional supplements and cosmetic products with major operations in China. The company recently announced that it entered into two distinct five-year marketing and distribution deals with San Deigo-based GenWay Biotech Inc.
GenWay Biotech will market and distribute AMDL’s DR-70 noninvasive cancer detection test in the U.S. and Canada.
DR-70 is an in vitro diagnostic test that enables physicians and patients to effectively monitor and/or detect certain types of cancers by measuring the Fibrin and Fibrinogen Degradation Products (FDP), which rise dramatically with the progression of cancer.
AMDL received FDA approval for DR-70 in the second quarter of fiscal year 2008 and immediately began executing a marketing and distribution strategy for the product.
According to the terms of the deal, GenWay Biotech has the rights to market and distribute AMDL's DR-70 (FDP) cancer test for uses other than colorectal cancer to CLIA-certified laboratories in the US and as a lung cancer screen to laboratories in Canada.
NEXT PAGE >>
Costa Mesa’s Oxygen Biotherapeutics inks deal with U.S. Navy
UC Irvine banks $45 million for infectious disease research
NIH: Masimo's SpCo may gauge asthma severity in kids
May is Huntington's Disease Awareness month
UC Irvine Medical Center lands stroke therapy center designation